{"id":547487,"date":"2023-02-03T22:18:48","date_gmt":"2023-02-03T19:18:48","guid":{"rendered":"https:\/\/en.buradabiliyorum.com\/leveraging-allogeneic-dendritic-cells-for-neoantigen-cancer-vaccines\/"},"modified":"2023-02-03T22:18:48","modified_gmt":"2023-02-03T19:18:48","slug":"leveraging-allogeneic-dendritic-cells-for-neoantigen-cancer-vaccines","status":"publish","type":"post","link":"https:\/\/buradabiliyorum.com\/en\/leveraging-allogeneic-dendritic-cells-for-neoantigen-cancer-vaccines\/","title":{"rendered":"#Leveraging allogeneic dendritic cells for neoantigen cancer vaccines"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a3ed741102bf\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #dd3333;color:#dd3333\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #dd3333;color:#dd3333\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a3ed741102bf\" checked aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/buradabiliyorum.com\/en\/leveraging-allogeneic-dendritic-cells-for-neoantigen-cancer-vaccines\/#%E2%80%9CLeveraging_allogeneic_dendritic_cells_for_neoantigen_cancer_vaccines%E2%80%9D\" >&#8220;Leveraging allogeneic dendritic cells for neoantigen cancer vaccines&#8221;<\/a><\/li><\/ul><\/nav><\/div>\n<h1><span class=\"ez-toc-section\" id=\"%E2%80%9CLeveraging_allogeneic_dendritic_cells_for_neoantigen_cancer_vaccines%E2%80%9D\"><\/span>&#8220;Leveraging allogeneic dendritic cells for neoantigen cancer vaccines&#8221;<span class=\"ez-toc-section-end\"><\/span><\/h1>\n<div>\n<div class=\"article-gallery lightGallery\">\n<div data-thumb=\"https:\/\/scx1.b-cdn.net\/csz\/news\/tmb\/2023\/genes-amp-cancer--leve.jpg\" data-src=\"https:\/\/scx2.b-cdn.net\/gfx\/news\/2023\/genes-amp-cancer--leve.jpg\" data-sub-html=\"The use of PDC*vac platform to develop NeoAg-based cancer vaccines. Credit: 2023 Hannani et al.\">\n<figure class=\"article-img\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/scx1.b-cdn.net\/csz\/news\/800a\/2023\/genes-amp-cancer--leve.jpg\" alt=\"Genes &amp;amp; Cancer | Leveraging allogeneic dendritic cells for neoantigen cancer vaccines\" title=\"The use of PDC*vac platform to develop NeoAg-based cancer vaccines. Credit: 2023 Hannani et al.\" width=\"800\" height=\"399\"\/><figcaption class=\"text-darken text-low-up text-truncate-js text-truncate mt-3\">\n                The use of PDC*vac platform to develop NeoAg-based cancer vaccines. Credit: 2023 Hannani et al.<br \/>\n            <\/figcaption><\/figure>\n<\/div>\n<\/div>\n<p>A new research perspective was published in <i>Genes &amp; Cancer<\/i> on January 30, 2023, entitled, &#8220;Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines.&#8221;\n                                                <\/p>\n<p>In recent years, immunotherapy has finally found its place in the anti-cancer therapeutic arsenal, even becoming standard of care as first line treatment for metastatic forms. The clinical benefit provided by checkpoint blockers such as anti-PD-1\/PD-L1 in many cancers revolutionized the field. However, too many patients remain refractory to these treatments due to weak baseline anti-cancer immunity.<\/p>\n<p>There is therefore a need to boost the frequency and function of patients&#8217; cytotoxic CD8+ cellular effectors by targeting immunogenic and tumor-restricted antigens, such as neoantigens using an efficient vaccination platform. Dendritic cells (DC) are the most powerful immune cell subset for triggering cellular immune response. However, autologous DC-based vaccines display several limitations, such as the lack of reproducibility and the limited number of cells that can be manufactured.<\/p>\n<p>In this new research perspective, researchers Dalil Hannani, Estelle Leplus, Karine Laulagnier, Laurence Chaperot, and Jo\u00ebl Plumas from PDC*line Pharma and Etablissement Fran\u00e7ais du Sang Auvergne Rh\u00f4ne-Alpes (EFS AURA) discuss the advantages of a new therapeutic vaccine based on an allogeneic Plasmacytoid DC cell line, which is easy to produce and represents a powerful platform for priming and expanding anti-neoantigen cytotoxic CD8+ T-cells.<\/p>\n<p>&#8220;NeoAgs <a href=\"https:\/\/buradabiliyorum.com\/en\/category\/download-scripts-themes-apps\/\" data-internallinksmanager029f6b8e52c=\"9\" title=\"Download Scripts &amp; Themes &amp; Apps\" target=\"_blank\" rel=\"noopener\">app<\/a>ear attractive candidates to induce specific anti-tumor responses in cancer patients, on top of classical tumor-associated antigens and in association with ICIs. A potent dendritic cell product such as PDC*neo represents a valuable platform to develop NeoAg-based cancer vaccines. We strongly believe that this new delivery <a href=\"https:\/\/buradabiliyorum.com\/en\/category\/technology\/\" data-internallinksmanager029f6b8e52c=\"4\" title=\"Technology\" target=\"_blank\" rel=\"noopener\">technology<\/a> based on potent PDC*line cells can induce a robust anti-NeoAg CD8+ T-cell immune response for the benefit of patients and could reshape the landscape of NeoAg-based cancer vaccines,&#8221; conclude the researchers.<\/p>\n<figure class=\"mb-4\" itemscope=\"\" itemtype=\"http:\/\/schema.org\/VideoObject\"><meta itemprop=\"name\" content=\"Leveraging allogeneic dendritic cells for neoantigen cancer vaccines\"\/><meta itemprop=\"url\" content=\"https:\/\/www.youtube.com\/watch\/?v=oPnYwGkmT54\"\/><meta itemprop=\"description\" content=\"Credit: Impact Journals LLC\"\/><meta itemprop=\"uploadDate\" content=\"2023-02-03T14:12:21-05:00\"\/><meta itemprop=\"embedUrl\" content=\"https:\/\/www.youtube.com\/embed\/oPnYwGkmT54\"\/><meta itemprop=\"thumbnailUrl\" content=\"https:\/\/img.youtube.com\/vi\/oPnYwGkmT54\/maxresdefault.jpg\"\/><\/p>\n<p>\n             <iframe loading=\"lazy\" title=\"Leveraging Powerful Allogeneic DC Line Towards Neoantigen-Based Cancer Vaccines | Genes &amp; Cancer\" width=\"640\" height=\"360\" src=\"https:\/\/www.youtube.com\/embed\/oPnYwGkmT54?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><figcaption class=\"text-darken text-low-up mt-4\" itemprop=\"caption\">Credit: Impact Journals LLC<\/figcaption><\/figure>\n<\/p>\n<div class=\"article-main__more p-4\">\n                                                                                                    <strong>More information:<\/strong><br \/>\n                                                    Dalil Hannani et al, Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines, <i>Genes &amp; Cancer<\/i> (2023).  <a rel=\"nofollow noopener\" target=\"_blank\" data-doi=\"1\" href=\"https:\/\/dx.doi.org\/10.18632\/genesandcancer.229\">DOI: 10.18632\/genesandcancer.229<\/a><\/p>\n<\/div>\n<p>\n                                                Provided by<br \/>\n                                                                                                    Impact Journals LLC<\/p>\n<p>                                        <!-- print only --><\/p>\n<div class=\"d-none d-print-block\">\n<p>                                                 <strong>Citation<\/strong>:<br \/>\n                                                 Leveraging allogeneic dendritic cells for neoantigen cancer vaccines (2023, February 3)<br \/>\n                                                 retrieved 3 February 2023<br \/>\n                                                 from https:\/\/medicalxpress.com\/<a href=\"https:\/\/buradabiliyorum.com\/en\/category\/news\/\" data-internallinksmanager029f6b8e52c=\"2\" title=\"News\" target=\"_blank\" rel=\"noopener\">news<\/a>\/2023-02-leveraging-allogeneic-dendritic-cells-neoantigen.html<\/p>\n<p>                                            This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no<br \/>\n                                            part may be reproduced without the written permission. The content is provided for information purposes only.<\/p><\/div>\n<\/p><\/div>\n<p><script id=\"facebook-jssdk\" async=\"\" src=\"https:\/\/connect.facebook.net\/en_US\/sdk.js\"><\/script><\/p>\n<blockquote><p><strong><span style=\"color: #ff6600;\">If you liked the article, do not forget to share it with your friends. Follow us on\u00a0<span style=\"color: #ff0000;\"><a style=\"color: #ff0000;\" href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMLG0nwswvr63Aw\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">Google News<\/a><\/span>\u00a0too, click on the star and choose us from your favorites.<\/span><\/strong><\/p><\/blockquote>\n<blockquote>\n<p style=\"text-align: center;\">For forums sites go to <span style=\"color: #ff9900;\"><a style=\"color: #ff9900;\" href=\"https:\/\/forum.buradabiliyorum.com\/\" target=\"_blank\" rel=\"noopener\">Forum.BuradaBiliyorum.Com<\/a><\/span><\/strong>\n<\/p><\/blockquote>\n<blockquote>\n<p style=\"text-align: center;\"><strong>If you want to read more Like this articles, you can visit our <span style=\"color: #ff9900;\"><a style=\"color: #ff9900;\" href=\"https:\/\/en.buradabiliyorum.com\/science\/\" target=\"_blank\" rel=\"noopener\">Science category.<\/a><\/span><\/strong><\/p>\n<\/blockquote>\n<p><span style=\"color: black;\"><a style=\"color: #ff9900;\" href=\"https:\/\/medicalxpress.com\/news\/2023-02-leveraging-allogeneic-dendritic-cells-neoantigen.html\" target=\"_blank\" rel=\"noopener\">Source<\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Leveraging allogeneic dendritic cells for neoantigen cancer vaccines&#8221; The use of PDC*vac platform to develop NeoAg-based cancer vaccines. Credit: 2023 Hannani et al. A new research perspective was published in Genes &amp; Cancer on January 30, 2023, entitled, &#8220;Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines.&#8221; In recent years, immunotherapy has finally&#8230;<\/p>\n","protected":false},"author":1,"featured_media":547488,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/scx2.b-cdn.net\/gfx\/news\/2023\/genes-amp-cancer--leve.jpg","fifu_image_alt":"","footnotes":""},"categories":[16],"tags":[],"class_list":["post-547487","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciencee"],"_links":{"self":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/547487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/comments?post=547487"}],"version-history":[{"count":0,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/547487\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media\/547488"}],"wp:attachment":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media?parent=547487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/categories?post=547487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/tags?post=547487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}